Other languages Takeda Pharmaceutical Company Limited Wiener Boerse

Equities

TKD

JP3463000004

Real-time Estimate Tradegate Other stock markets 12:01:24 2024-06-21 pm EDT			5-day change	1st Jan Change
23.72 ^EUR	-3.52%		+0.53%	-4.80%

08:50am	Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	MT
07:47am	Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	RE

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Les sorcières épouvantent l'IA	03:06am
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	02:50am
En Direct des Marchés : LVMH, Accor, Alstom, Atos, Casino, Plastivaloire, Boeing, Geberit...	02:41am
Borsa di Italia: Le streghe terrorizzano l'AI	02:00am
Bolsa de Madrid: Las brujas aterrorizan a la IA	02:00am
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	01:47am
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	11:59pm
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India	11:28pm
Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)	Jun. 19
Takeda presenta datos de largo plazo del ensayo clínico de fase 3 ADVANCE-CIDP 3 de HYQVIA® en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) en la Reunión Anual de la PNS	Jun. 19
Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung	Jun. 19
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	Jun. 18
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	Jun. 18
Sector Update: Health Care Stocks Decline Premarket Monday	Jun. 17
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	Jun. 17
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	Jun. 17
Takeda's seizure drug fails to meet main goal in late-stage studies	Jun. 17
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome	Jun. 17
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	Jun. 17
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	Jun. 14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Takeda Pharmaceutical Company Limited Wiener Boerse

Equities

TKD

JP3463000004

Other languages

Filters